These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36318757)

  • 1. Prostate-Specific Membrane Antigen Targeted Deep Tumor Penetration of Polymer Nanocarriers.
    Meher N; Ashley GW; Bidkar AP; Dhrona S; Fong C; Fontaine SD; Beckford Vera DR; Wilson DM; Seo Y; Santi DV; VanBrocklin HF; Flavell RR
    ACS Appl Mater Interfaces; 2022 Nov; 14(45):50569-50582. PubMed ID: 36318757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer.
    Meher N; Ashley GW; Bobba KN; Wadhwa A; Bidkar AP; Dasari C; Mu C; Sankaranarayanan RA; Serrano JAC; Raveendran A; Bulkley DP; Aggarwal R; Greenland NY; Oskowitz A; Wilson DM; Seo Y; Santi DV; VanBrocklin HF; Flavell RR
    Adv Healthc Mater; 2024 Jul; 13(19):e2304618. PubMed ID: 38700450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and Preliminary Biological Assessment of Carborane-Loaded Theranostic Nanoparticles to Target Prostate-Specific Membrane Antigen.
    Meher N; Seo K; Wang S; Bidkar AP; Fogarty M; Dhrona S; Huang X; Tang R; Blaha C; Evans MJ; Raleigh DR; Jun YW; VanBrocklin HF; Desai TA; Wilson DM; Ozawa T; Flavell RR
    ACS Appl Mater Interfaces; 2021 Nov; 13(46):54739-54752. PubMed ID: 34752058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
    Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE
    Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
    Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
    J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single Chelator-Minibody Theranostic Agents for
    Ho KV; Tatum DS; Watkinson L; Carmack T; Jia F; Mascioni A; Maitz CA; Magda D; Anderson CJ
    J Nucl Med; 2024 Sep; 65(9):1435-1442. PubMed ID: 39142831
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Banerjee SR; Foss CA; Horhota A; Pullambhatla M; McDonnell K; Zale S; Pomper MG
    Biomacromolecules; 2017 Jan; 18(1):201-209. PubMed ID: 28001364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small Molecule, Multimodal, [
    Aras O; Demirdag C; Kommidi H; Guo H; Pavlova I; Aygun A; Karayel E; Pehlivanoglu H; Yeyin N; Kyprianou N; Chen N; Harmsen S; Sonmezoglu K; Lundon DJ; Oklu R; Ting R; Tewari A; Akin O; Sayman HB
    Clin Genitourin Cancer; 2021 Oct; 19(5):405-416. PubMed ID: 33879400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Prostate-Specific Membrane-Antigen (PSMA) Targeted Micelle-Encapsulating Wogonin Inhibits Prostate Cancer Cell Proliferation via Inducing Intrinsic Apoptotic Pathway.
    Zhang H; Liu X; Wu F; Qin F; Feng P; Xu T; Li X; Yang L
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
    Kelly JM; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; DiMagno SG; Babich JW
    J Nucl Med; 2019 May; 60(5):656-663. PubMed ID: 30552199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors.
    Ngen EJ; Chen Y; Azad BB; Boinapally S; Jacob D; Lisok A; Shen C; Hossain MS; Jin J; Bhujwalla ZM; Pomper MG; Banerjee SR
    Nanotheranostics; 2021; 5(2):182-196. PubMed ID: 33564617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation.
    Lesniak WG; Boinapally S; Lofland G; Jiang Z; Foss CA; Behman Azad B; Jablonska A; Garcia MA; Brzezinski M; Pomper MG
    Int J Nanomedicine; 2024; 19():4995-5010. PubMed ID: 38832336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M; Umbricht CA; Schibli R; Müller C
    Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.
    Chen Y; Lisok A; Chatterjee S; Wharram B; Pullambhatla M; Wang Y; Sgouros G; Mease RC; Pomper MG
    Bioconjug Chem; 2016 Jul; 27(7):1655-62. PubMed ID: 27270097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a bimodal, matched pair theranostic agent targeting prostate-specific membrane antigen.
    Lewis MR; Schaedler AW; Ho KV; Golzy M; Mathur A; Pun M; Gallazzi F; Watkinson LD; Carmack TL; Sikligar K; Anderson CJ; Smith CJ
    Nucl Med Biol; 2024; 136-137():108938. PubMed ID: 39032262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
    Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG
    Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of
    Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S
    Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
    Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C
    Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics.
    Huynh TT; Feng Y; Meshaw R; Zhao XG; Rosenfeld L; Vaidyanathan G; Papo N; Zalutsky MR
    Nucl Med Biol; 2024; 134-135():108913. PubMed ID: 38703588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.
    Kiess AP; Minn I; Vaidyanathan G; Hobbs RF; Josefsson A; Shen C; Brummet M; Chen Y; Choi J; Koumarianou E; Baidoo K; Brechbiel MW; Mease RC; Sgouros G; Zalutsky MR; Pomper MG
    J Nucl Med; 2016 Oct; 57(10):1569-1575. PubMed ID: 27230930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.